secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K/A
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018499
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs corrects Q1 EPS to $(0.35) from $(0.07); net loss $6.3M on revenue decline
--------------------------------------------------------------------------------

- Corrected diluted EPS $(0.35) vs originally $(0.07); weighted average shares corrected to 18.0M from 90.4M.
- Q1 net loss of $6.3M vs net income of $0.6M a year ago; revenue fell 81% to $3.6M as COVID testing ended.
- Pharmaloz exploring potential sale or long-term capacity agreements; line two expected $40-$45M revenue capacity in Q3.
- BE-Smart esophageal cancer test on track for H2 2024 commercialization; launched AI initiative Project ZenQ-AI.
- Cash at April 30 was $4.6M; raised $2.5M via receivable securitization and collected $3.6M from partial investment sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224018499/0001493152-24-018499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224018499/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer